 That can be a weakness. Because, of course, as an investor, you're thinking, well, at least I know they've got this huge safety net of billions and billions of cash set aside. But in fact, one of the lines from the book, wealth, shirt sleeves to shirt sleeves in a few generations, that having too much money actually can create a lot of problems and bad incentives inside that system. I'm convinced this is at the heart of the R&D drought in big pharma.